Edgewise Therapeutics, Inc.

EWTX

$44.64

Updated: 22/09/2026, 09:58:32

Market Cap

$4.80B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for EWTX

Company Profile

Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.

USD

NASDAQ

CEO: Kevin Koch

Employees: 127

https://www.edgewisetx.com

Asset Summaries

Latest generated summaries for EWTX

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for EWTX.

Share price: $44.64
Market cap: $4.80B
Exchange: NASDAQ
Currency: USD
CEO: Kevin Koch
Employees: 127
IPO date: 26/03/2021
Beta: 0.275
Last dividend: $0.00
Day range: $44.51 – $45.96
52-week range: $14.25 – $48.51
1-day performance: -1.50%
1-year performance: 213.26%
Current drawdown (1Y): -7.98%
CIK: 0001710072
CUSIP: 28036F105
ISIN: US28036F1057
Created: 07/12/2025, 03:52:41
Last update: 22/09/2026, 09:58:32

Track Edgewise Therapeutics, Inc. with an AI analyst

See which prediction-market events move EWTX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to EWTX from your Railway `news_articles` table.

Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement

Seeking Alpha • STOCK • 05/06/2026, 01:37:34

Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal

Zacks Investment Research • STOCK • 02/06/2026, 14:15:27

Edgewise to sell muscle dystrophy business to Servier for up to $2.65 billion

Reuters • STOCK • 01/06/2026, 10:34:59

Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

PRNewsWire • STOCK • 01/06/2026, 10:30:00

Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up

PRNewsWire • STOCK • 10/03/2026, 08:00:00

Why Edgewise Therapeutics Stock Crushed the Market on Monday

The Motley Fool • STOCK • 09/02/2026, 21:05:54